Clinical Trials Logo

Clinical Trial Summary

A multicenter,randomized,single-blind, placebo-controlled,phase 4 clinical trial to evaluate the efficacy and safety of andrographolide sulfonate in patients with acute exacerbation of chronic bronchitis


Clinical Trial Description

The patient after passing the screening, with the ratio of 1:1, were randomly assigned to experimental group or control group. Experimental group: on the basis of Conventional Therapy,Xiyanping injection(andrographolide sulfonate) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops. control group: on the basis of Conventional Therapy,Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03132610
Study type Interventional
Source Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contact Lang Lv
Phone +86 010-84682600
Email bjlll@qfyy.com.cn
Status Recruiting
Phase Phase 4
Start date December 1, 2016
Completion date June 1, 2018

See also
  Status Clinical Trial Phase
Completed NCT01979926 - Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis Phase 2
Recruiting NCT03400735 - Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults Phase 4